Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance

Rhea-AI Summary

Pfizer (NYSE: PFE) reported robust second-quarter 2024 financial results, driving a raise in full-year 2024 revenue guidance to $59.5-$62.5 billion and adjusted diluted EPS to $2.45-$2.65. The company's revenue hit $13.3 billion, growing 3% operationally year-over-year, despite a decline in COVID-related revenues. Excluding Comirnaty and Paxlovid, revenues surged by 14%. Reported diluted EPS was $0.01, impacted by $1.3 billion in one-time manufacturing optimization costs, while adjusted diluted EPS was $0.60. Pfizer anticipates $1.5 billion in cost savings from its Manufacturing Optimization Program by 2027.

Key product highlights include a 71% operational growth for the Vyndaqel family, 8% for Eliquis, and 44% for Nurtec ODT/Vydura. However, Xeljanz and Ibrance saw declines of 34% and 8% operationally, respectively. Pfizer also announced advancements in its R&D pipeline and several product developments.

Positive

• Raised full-year 2024 revenue guidance to $59.5-$62.5 billion.
• Raised adjusted diluted EPS guidance to $2.45-$2.65.
• Operational revenue growth of 14% excluding Comirnaty and Paxlovid.
• 71% operational revenue growth for Vyndaqel family.
• 8% operational revenue growth for Eliquis.
• 44% operational revenue growth for Nurtec ODT/Vydura.
• Anticipated $1.5 billion in cost savings from Manufacturing Optimization Program by 2027.

Negative

• Second-quarter reported diluted EPS negatively impacted by $1.3 billion in one-time manufacturing optimization costs.
• 98% decline in reported net income year-over-year.
• 87% operational decline in Comirnaty revenues.
• 34% operational decline in Xeljanz revenues.
• 8% operational decline in Ibrance revenues.

Financial Analyst

Pfizer's Q2 2024 results demonstrate the company's resilience and strategic execution in a post-COVID landscape. Key takeaways:

• Revenues of $13.3 billion, up 3% operationally year-over-year, beating expectations despite anticipated COVID product declines.
• Excluding COVID products, revenues grew an impressive 14% operationally, driven by acquired products, key in-line brands and new launches.
• Adjusted EPS of $0.60, down 11% but above consensus estimates.
• Full-year 2024 guidance raised: Revenues now $59.5-$62.5 billion (up $1 billion at midpoint) and adjusted EPS $2.45-$2.65 (up $0.30 at midpoint).

The 14% operational growth in non-COVID products is particularly encouraging, showcasing Pfizer's underlying strength. The Seagen acquisition is already contributing meaningfully with $845 million in Q2 revenues. Other growth drivers like Vyndaqel (+71%) and Eliquis (+8%) demonstrate the company's diverse portfolio.

Pfizer's cost optimization efforts, including the new Manufacturing Optimization Program targeting $1.5 billion in savings by 2027, should help improve margins. The raised guidance reflects management's confidence in the company's trajectory.

While challenges remain, including patent expirations for key products like Ibrance and Xeljanz, Pfizer's robust pipeline and strategic moves position it well for future growth. Investors should monitor the progress of recent launches and pipeline developments, particularly in oncology following the Seagen acquisition.

Pharmaceutical Industry Expert

Pfizer's Q2 results highlight its successful pivot beyond COVID-19 products, demonstrating the strength of its core business and recent strategic moves. Key observations:

• The 14% operational growth in non-COVID products underscores Pfizer's diverse portfolio and commercial execution.
• Oncology is emerging as a key growth driver, bolstered by the Seagen acquisition and strong performance of existing products.
• The company's focus on rare diseases is paying off, with Vyndaqel family revenues surging 71% operationally.
• Pfizer's R&D engine continues to deliver, with promising pipeline developments in gene therapy and mRNA technology.

The raised guidance for 2024 reflects confidence in the company's strategy and execution. However, challenges remain, including:

• Declining revenues for mature products like Xeljanz and Ibrance due to patent expirations and competitive pressures.
• The need to successfully integrate Seagen and leverage its capabilities across the oncology portfolio.
• Executing on cost optimization initiatives while maintaining innovation and growth.

Pfizer's advancement of danuglipron, an oral GLP-1 agonist, is particularly noteworthy given the explosive growth in the weight loss market. If successful, this could represent a significant opportunity.

The setback with the DMD gene therapy highlights the risks inherent in cutting-edge research, but Pfizer's broad pipeline helps mitigate such risks. Overall, Pfizer's transformation from a COVID-19 powerhouse to a diversified biopharma leader appears to be on track, positioning the company well for sustainable long-term growth.

Medical Research Analyst

Pfizer's Q2 results and pipeline updates reveal significant progress in key therapeutic areas, particularly oncology and rare diseases. Notable developments include:

• Positive data for Adcetris in relapsed/refractory DLBCL, potentially expanding its utility in lymphoma treatment.
• Promising long-term data for Lorbrena in ALK-positive NSCLC, solidifying its position in lung cancer therapy.
• Advancement of danuglipron, an oral GLP-1 agonist, addressing the rapidly growing obesity market.
• Positive Phase 3 results for giroctocogene fitelparvovec in hemophilia A, showcasing Pfizer's progress in gene therapy.
• Encouraging early data for the mRNA-based pandemic influenza vaccine, leveraging Pfizer's COVID-19 vaccine expertise.

These developments underscore Pfizer's commitment to innovation across multiple modalities, from small molecules to biologics and gene therapies. The company's focus on oncology, bolstered by the Seagen acquisition, is particularly noteworthy.

However, the failure of fordadistrogene movaparvovec in DMD highlights the challenges in gene therapy development. This setback emphasizes the importance of Pfizer's diverse pipeline in mitigating risks.

The advancement of danuglipron is strategically important, given the massive potential of the GLP-1 market. If successful, an oral formulation could be highly competitive in this space.

Pfizer's progress in mRNA technology beyond COVID-19 vaccines demonstrates the platform's broader potential, which could drive future growth opportunities.

Overall, Pfizer's R&D efforts appear well-aligned with key areas of unmet medical need and emerging therapeutic modalities, positioning the company for continued innovation and potential breakthroughs.

• Second-Quarter Performance Driven by Focused Commercial Execution
• Raises Full-Year 2024 Revenue Guidance⁽¹⁾ to a Range of $59.5 to $62.5 Billion and Raises Adjusted⁽²⁾ Diluted EPS Guidance to a Range of $2.45 to $2.65
• Launched Manufacturing Optimization Program with Anticipated Cost Savings of Approximately $1.5 Billion by the End of 2027
• Second-Quarter 2024 Revenues of $13.3 Billion
  • Revenues Grew 3% Operationally Year-over-Year Despite Anticipated Decline in COVID Revenues
  • Excluding Contributions from Comirnaty⁽³⁾ and Paxlovid, Revenues Grew 14% Operationally
• Second-Quarter 2024 Reported⁽⁴⁾ Diluted EPS of $0.01 and Adjusted⁽²⁾ Diluted EPS of $0.60
  • Includes $1.3 Billion of One-Time Costs for Manufacturing Optimization Program, Negatively Impacting Reported⁽⁴⁾ Diluted EPS by $0.18⁽⁵⁾
• On Track to Deliver at Least $4 Billion in Net Cost Savings by End of 2024 from Previously Announced Cost Realignment Program⁽⁶⁾

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2024 and raised its full-year 2024 guidance⁽¹⁾ for both Revenues and Adjusted⁽²⁾ diluted EPS.

The second-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We are driving progress toward our 2024 strategic priorities through solid execution across the company. I am pleased with the strong performance of our product portfolio in the second quarter led by several of our acquired products, key in-line brands and recent commercial launches. Notably, we achieved exceptional growth in our Oncology portfolio, with strong revenue contribution from our legacy-Seagen products.

“Overall, I am encouraged by our performance in the first half of 2024 and we remain focused on making a difference in the lives of patients as we continue to advance and strengthen our company.”

David Denton, Chief Financial Officer and Executive Vice President, stated: “This was Pfizer’s first quarter of topline revenue growth, on a year-over-year basis, since the fourth quarter of 2022 when our COVID revenues peaked. Importantly, the strong 14% operational revenue growth of our non-COVID products in the second quarter demonstrates our continued focus on commercial execution. In support of our stated strategic priority to realign our cost base, we continue to progress our cost realignment program. Additionally, with our more recent announcement of the first phase of our Manufacturing Optimization Program, we believe we are setting the foundation for future margin expansion.”

OVERALL RESULTS

In the first quarter of 2024, Pfizer reclassified royalty income (substantially all of which is related to our Biopharma segment) from Other (income)/deductions––net to revenues and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations. Prior-period amounts have been recast to conform to the current presentation.

At the beginning of 2024, Pfizer made changes in our commercial organization to incorporate Seagen Inc. (Seagen) and improve focus, speed and execution. Specifically, within our Biopharma reportable segment Pfizer created the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. See the Item 1. Business––Commercial Operations section of Pfizer’s 2023 Annual Report on Form 10-K (available at www.pfizer.com).

Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates⁽⁷⁾.

Results for the second quarter and first six months of 2024 and 2023⁽⁸⁾ are summarized below.

($ in millions, except per share amounts)	Second-Quarter					Six Months
	2024		2023		Change	2024		2023		Change
Revenues	$	13,283	$	13,007	2%	$	28,162	$	31,492	(11%)
Reported(4) Net Income		41		2,327	(98%)		3,156		7,870	(60%)
Reported(4) Diluted EPS		0.01		0.41	(98%)		0.55		1.38	(60%)
Adjusted(2) Income		3,400		3,839	(11%)		8,074		10,876	(26%)
Adjusted(2) Diluted EPS		0.60		0.67	(11%)		1.42		1.90	(25%)

REVENUES

($ in millions)	Second-Quarter							Six Months
	2024		2023		% Change			2024		2023		% Change
					Total	Oper.						Total	Oper.
Global Biopharmaceuticals Business (Biopharma)	$	12,991	$	12,690	2%	4%		$	27,595	$	30,863	(11%)	(10%)
Pfizer CentreOne (PC1)		278		307	(10%)	(9%)			535		615	(13%)	(13%)
Pfizer Ignite		15		10	47%	47%			32		14	*	*
TOTAL REVENUES	$	13,283	$	13,007	2%	3%		$	28,162	$	31,492	(11%)	(10%)
* Indicates calculation not meaningful.

2024 FINANCIAL GUIDANCE⁽¹⁾

Pfizer raises full-year 2024 revenue guidance by $1 billion at the midpoint to a range of $59.5 to $62.5 billion and raises Adjusted⁽²⁾ diluted EPS guidance by $0.30 at the midpoint to $2.45 to $2.65. The company’s updated guidance for revenue includes approximately $8.5 billion in anticipated revenues for Comirnaty⁽³⁾ and Paxlovid, approximately $5 billion and $3.5 billion, respectively. Including the contribution from Seagen and excluding revenues from Comirnaty⁽³⁾ and Paxlovid, Pfizer now expects to achieve full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenues, up from 8% to 10% provided on January 30, 2024.

The updated 2024 Adjusted⁽²⁾ diluted EPS guidance takes into consideration our strong first half performance as well as our continued confidence in the underlying strength of our business.

Pfizer’s updated financial guidance⁽¹⁾ is presented below.

Revenues	$59.5 to $62.5 billion
	(previously $58.5 to $61.5 billion)
Adjusted(2) SI&A Expenses	$13.8 to $14.8 billion
Adjusted(2) R&D Expenses	$11.0 to $12.0 billion
Effective Tax Rate on Adjusted(2) Income	Approximately 13.0%
	(previously approximately 15.0%)
Adjusted(2) Diluted EPS	$2.45 to $2.65
	(previously $2.15 to $2.35)

Changes in foreign exchange rates have had a minimal incremental impact since full-year 2024 guidance was updated on May 1, 2024. Please refer to Press Release Footnote (1) for additional information.

CAPITAL ALLOCATION

During the first six months of 2024, Pfizer deployed its capital in a variety of ways, which primarily include the following two categories:

• Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including:
  • $5.2 billion invested in internal research and development projects, and
  • Approximately $200 million invested in business development transactions.
• Returning capital directly to shareholders through $4.8 billion of cash dividends, or $0.84 per share of common stock.

No share repurchases were completed to date in 2024. As of July 30, 2024, Pfizer’s remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2024.

Second-quarter 2024 diluted weighted-average shares outstanding used to calculate Reported⁽⁴⁾ and Adjusted⁽²⁾ diluted EPS were 5,696 million shares.

QUARTERLY FINANCIAL HIGHLIGHTS (Second-Quarter 2024 vs. Second-Quarter 2023)

Second-quarter 2024 revenues totaled $13.3 billion, an increase of $277 million, or 2%, compared to the prior-year quarter, reflecting an operational increase of $447 million, or 3%, primarily due to growth contributions from several of our acquired products, key in-line products, and recent commercial launches, which more than offset both an expected decline in Comirnaty⁽³⁾ revenues globally and an unfavorable impact of foreign exchange of $170 million, or 1%. Excluding contributions from Comirnaty⁽³⁾ and Paxlovid, revenues totaled $12.8 billion, an increase of $1.6 billion, or 14%, operationally compared with the prior-year quarter.

Second-quarter 2024 Comirnaty⁽³⁾ revenues of $195 million declined $1.3 billion, or 87%, operationally compared with the prior-year quarter, driven largely by lower contractual deliveries and demand in international markets, reflecting the anticipated seasonality of demand for vaccinations and as certain markets, including the U.S., transition to traditional commercial market sales.

Second-quarter 2024 Paxlovid revenues of $251 million increased $112 million, or 79%, operationally compared with the prior-year quarter, driven primarily by no second quarter 2023 U.S. sales in anticipation of transition to commercial markets in the second half of 2023, as well as increases in infections and demand in certain international markets in the second quarter of 2024.

Excluding contributions from Comirnaty⁽³⁾ and Paxlovid, second-quarter 2024 operational revenue growth was driven primarily by:

• Global revenues of $845 million from legacy Seagen, which was acquired in December of 2023;
• Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 71% operationally, driven largely by continued strong demand, primarily in the U.S. and international developed markets;
• Eliquis globally, up 8% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of patent-based exclusivity and generic competition in certain international markets; and
• Nurtec ODT/Vydura globally, up 44% operationally, driven primarily by strong demand in the U.S. as well as recent launches in international markets;

partially offset primarily by lower revenues for:

• Xeljanz globally, down 34% operationally, driven primarily by decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to label changes, as well as lower net price in the U.S. due to unfavorable changes in channel mix and the impact of regulatory exclusivity expiry in Canada; and
• Ibrance globally, down 8% operationally, driven primarily by lower demand due to competitive pressure globally and price decreases in certain international developed markets, partially offset by increased clinical trial supply orders in certain international developed markets versus prior year.

GAAP Reported⁽⁴⁾ Statement of Operations Highlights

SELECTED REPORTED⁽⁴⁾ COSTS AND EXPENSES

($ in millions)	Second-Quarter								Six Months
	2024		2023		% Change				2024		2023		% Change
					Total	Oper.							Total	Oper.
Cost of Sales(4)	$	3,300	$	3,237	2%	5%			$	6,679	$	8,122	(18%)	(15%)
Percent of Revenues		24.8%		24.9%	N/A	N/A				23.7%		25.8%	N/A	N/A
SI&A Expenses(4)		3,717		3,497	6%	7%				7,212		6,914	4%	5%
R&D Expenses(4)		2,696		2,648	2%	2%				5,189		5,153	1%	1%
Acquired IPR&D Expenses(4)		6		33	(81%)	(81%)				6		55	(88%)	(88%)
Other (Income)/Deductions—net(4)		1,107		(75)	*	*				1,787		200	*	*
Effective Tax Rate on Reported(4) Income		130.2%		(3.1%)						4.8%		7.5%
* Indicates calculation not meaningful.

Second-quarter 2024 Cost of Sales⁽⁴⁾ as a percentage of revenues was relatively flat compared with the prior-year quarter, and reflects favorable changes in sales mix, primarily driven by lower sales of Comirnaty⁽³⁾, which resulted in a lower related charge for the 50% gross profit split with BioNTech and applicable royalty expenses in the quarter; offset by the amortization of the fair value step-up of inventory related to the Seagen acquisition.

Second-quarter 2024 SI&A Expenses⁽⁴⁾ increased 7% operationally compared with the prior-year quarter, driven primarily by an increase in marketing and promotional expenses for recently launched and acquired products.

Second-quarter 2024 R&D Expenses⁽⁴⁾ increased 2% operationally compared with the prior-year quarter, primarily due to increased spending to develop certain medicines acquired from Seagen, partially offset by lower spending primarily as a result of our cost realignment program.

The unfavorable period-over-period change in Other deductions—net⁽⁴⁾ of $1.2 billion for the second quarter of 2024, compared with the prior-year quarter, was driven primarily by net losses on equity securities in the second quarter of 2024 versus net gains on equity securities recognized in the prior-year quarter, higher net interest expense and intangible asset impairment charges in the second quarter of 2024.

Pfizer’s effective tax rate on Reported⁽⁴⁾ income for the second quarter of 2024 increased compared to the prior-year quarter primarily due to the non-recurrence of tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years in the second quarter of 2023, partially offset by a favorable change in the jurisdictional mix of earnings in the second quarter of 2024.

Adjusted⁽²⁾ Statement of Operations Highlights

SELECTED ADJUSTED⁽²⁾ COSTS AND EXPENSES

($ in millions)	Second-Quarter								Six Months
	2024		2023		% Change				2024		2023		% Change
					Total	Oper.							Total	Oper.
Adjusted(2) Cost of Sales	$	2,768	$	3,072	(10%)	(6%)			$	5,804	$	7,818	(26%)	(23%)
Percent of Revenues		20.8%		23.6%	N/A	N/A				20.6%		24.8%	N/A	N/A
Adjusted(2) SI&A Expenses		3,669		3,419	7%	8%				7,123		6,769	5%	6%
Adjusted(2) R&D Expenses		2,671		2,627	2%	2%				5,147		5,118	1%	1%
Adjusted(2) Other (Income)/Deductions—net		258		(278)	*	*				555		(601)	*	*
Effective Tax Rate on Adjusted(2) Income		12.9%		6.8%						15.1%		11.6%
* Indicates calculation not meaningful.

See the reconciliations of certain Reported⁽⁴⁾ to non-GAAP Adjusted⁽²⁾ financial measures and associated footnotes in the financial tables section of this press release located at the hyperlink below.

RECENT NOTABLE DEVELOPMENTS (Since May 1, 2024)

Product Developments

Product/Project	Recent Development	Link
Adcetris (brentuximab vedotin)	July 2024. Pfizer’s supplemental Biologics License Application (sBLA) for Adcetris in combination with lenalidomide and rituximab for patients with relapsed/refractory large B-cell lymphoma was accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 2025. If approved, this would be the eighth FDA-approved indication for Adcetris.	N/A
	June 2024. Presented detailed overall survival (OS) results from the investigational Phase 3 ECHELON-3 study of Adcetris in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Detailed data from the study demonstrated the investigational Adcetris regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median OS of 13.8 months versus 8.5 months. The most frequently reported treatment-emergent adverse events Grade 3 or higher for the Adcetris versus placebo arms were neutropenia, thrombocytopenia and anemia.	Full Release
	June 2024. Takeda and Pfizer announced positive results from the Phase 3 HD21 trial evaluating Adcetris in combination with intensive chemotherapy. The four-year analysis conducted and presented by the German Hodgkin Study Group (GHSG) at the 2024 ASCO Annual Meeting and at the European Hematology Association (EHA) Annual Meeting showed superior progression-free survival (PFS) and improved tolerability for patients with newly diagnosed Stage IIb/III/IV classical Hodgkin Lymphoma compared to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (eBEACOPP), a current standard of care regimen predominantly used in Europe in this setting.	Full Release
Comirnaty(3) (COVID-19 Vaccine, mRNA)	June 2024. Announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Pfizer and BioNTech’s Omicron JN.1-adapted monovalent COVID-19 vaccine (Comirnaty JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Subsequently, the European Commission (EC) authorized the vaccine on July 3, 2024.	Full Release
Durveqtix (fidanacogene elaparvovec)	July 2024. Announced the EC granted conditional marketing authorization for Durveqtix, a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74. This follows the EMA’s CHMP positive opinion adopted in May. Durveqtix has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for appropriate patients with hemophilia B. The EC approval follows recent regulatory approvals by the FDA and Health Canada, where it is marketed as Beqvez.	Full Release
Elrexfio (elranatamab bcmm)	June 2024. Presented detailed OS results from the Phase 2 MagnetisMM-3 study of Elrexfio in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) who had not received prior B-cell maturation antigen (BCMA)-directed therapy (i.e., BCMA-naïve; Cohort A; n=123) at EHA 2024. With a median follow-up of 28.4 months (estimated by the reverse-Kaplan-Meier method), the study demonstrated a median OS of 24.6 months, with median PFS of 17.2 months for the full intent-to-treat cohort. The safety and tolerability of Elrexfio in MagnetisMM-3 were consistent with what have been previously observed.	Full Release
Lorbrena (lorlatinib)	May 2024. Presented longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) at the ASCO Annual Meeting that were simultaneously published in the Journal of Clinical Oncology. Updated results showed an unprecedented 60% of patients remain alive without disease progression after five years, along with continued 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases compared to Xalkori. The safety profiles of Lorbrena and Xalkori in the five-year follow-up were consistent with previous findings, with no new safety signals reported for Lorbrena.	Full Release

Pipeline Developments

A comprehensive update of Pfizer’s development pipeline was published today and is now available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of Pfizer’s research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.

Product/Project	Recent Development	Link
danuglipron	July 2024. Announced advancement of development of once-daily formulation of oral glucagon-like peptide-1 (GLP-1) receptor agonist, danuglipron. Based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron. With these results, and following a thorough analysis of previous Phase 2b data and trial design, Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies.	Full Release
fordadistrogene movaparvovec	June 2024. Announced CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in motor function among boys 4 to 7 years of age treated with the gene therapy compared to placebo. Key secondary endpoints also did not show a significant difference between participants treated with fordadistrogene movaparvovec and placebo.	Full Release
giroctocogene fitelparvovec	July 2024. Announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment. Key secondary endpoints as defined by the trial protocol were met and also demonstrated superiority compared to prophylaxis. Giroctocogene fitelparvovec was generally well tolerated in the study. Pfizer will discuss these data with regulatory authorities in the coming months.	Full Release
Pandemic Influenza Vaccine Candidate	May 2024. Announced that preliminary results from a subset of patients randomized in a Phase 1 study (NCT06179446) evaluating the safety, tolerability, and immunogenicity of multiple doses of a nucleoside-modified mRNA (modRNA) based pandemic influenza vaccine candidate illustrated notable increases in antibody responses against the avian strain [H5, Clade 2.3.4.4b] of H5 influenza virus. Pfizer continues to monitor all developments regarding the circulation and outbreaks of the A/H5N1 virus. If a vaccine is needed in an emergency pandemic situation, Pfizer anticipates that the modRNA vaccine platform could be leveraged to rapidly provide a vaccine candidate targeting the specific pandemic influenza strain.	Full Release

Corporate Developments

Topic	Recent Development	Link
Board Election	July 2024. Announced Cyrus Taraporevala was elected to Pfizer’s Board of Directors. Mr. Taraporevala was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board.	Full Release
Executive Leadership	July 2024. Announced the launch of a process to identify a successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer R&D, who will depart the company after a 15+ year stellar career. Dr. Dolsten will assist in the external search for a new Chief Scientific Officer and continue to serve in his current position until his successor is in place and any necessary transition is complete.	Full Release
	May 2024. Announced Andrew Baum, M.D., would join the company as Chief Strategy and Innovation Officer, Executive Vice President, effective June 3, 2024, and will become a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. In his role, Dr. Baum will be responsible for Pfizer’s long-term corporate strategic plan, and Pfizer’s portfolio analysis and prioritization functions, business development activities, strengthening of partnerships with the biotech ecosystem, and the commercial evaluation of the company’s research pipeline.	Full Release
Manufacturing Optimization Program	May 2024. Announced the launch of the first phase of a multi-year, multi-phase cost reduction program (the “Manufacturing Optimization Program” or “the program”) to reduce our cost of goods sold. The program is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of the program is focused on operational efficiencies and is expected to deliver savings of approximately $1.5 billion by the end of 2027, some of which is expected to begin being realized in 2025. The one-time costs to achieve the savings associated with the first phase of the program are expected to be approximately $1.7 billion and primarily include severance and implementation costs. These costs will be recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026.	Form 8-K

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:

https://investors.pfizer.com/Q2-2024-PFE-Earnings-Release

(Note: If clicking on the above link does not open a new webpage, you may need to cut and paste the above URL into your browser's address bar.)

For additional details, see the financial schedules and product revenue tables attached to the press release located at the hyperlink above, and the attached disclosure notice.

(1)		Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.
		Financial guidance for full-year 2024 reflects the following:
		Does not assume the completion of any business development transactions not completed as of June 30, 2024. An anticipated immaterial impact in fiscal-year 2024 of recent and expected generic and biosimilar competition for certain products that have recently lost patent or regulatory protection or that are anticipated to lose patent or regulatory protection. Exchange rates assumed are a blend of actual rates in effect through second-quarter 2024 and mid-July 2024 rates for the remainder of the year. Financial guidance reflects the anticipated unfavorable impact of approximately $0.6 billion on revenues and the anticipated unfavorable impact of approximately $0.04 on Adjusted(2) diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2023. Guidance for Adjusted(2) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.7 billion shares, and assumes no share repurchases in 2024. Guidance assumes the seasonal cadence of certain products in our portfolio, and that Paxlovid results trend with infection rates.
(2)		Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the second quarter and the first six months of 2024 and 2023 in the press release located at the hyperlink above. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS(4). See the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2023 Annual Report on Form 10-K and the accompanying Non-GAAP Financial Measure: Adjusted Income section of the press release located at the hyperlink above for a definition of each component of Adjusted income as well as other relevant information.
(3)		As used in this document, “Comirnaty” refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; and Comirnaty JN.1. “Comirnaty” includes product revenues and alliance revenues related to sales of the above-mentioned vaccines.
(4)		Revenues is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP). Reported net income and its components are defined as net income attributable to Pfizer Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.
(5)		Second-quarter 2024 Reported(4) diluted EPS was unfavorably impacted by $0.18 resulting from a $1.3 billion one-time restructuring charge related to the Manufacturing Optimization Program.
(6)		The targeted $4 billion in net cost savings is calculated versus the midpoint of Pfizer’s 2023 SI&A and R&D expense guidance provided on August 1, 2023. As an additional reference, see the ‘2024 Financial Guidance’ section of Pfizer’s fourth-quarter 2023 earnings release.
(7)		References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of Pfizer’s business, they are not within Pfizer’s control and because they can mask positive or negative trends in the business, Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful information to evaluate Pfizer’s results.
(8)		Pfizer’s fiscal year-end for international subsidiaries is November 30 while Pfizer’s fiscal year-end for U.S. subsidiaries is December 31. Therefore, Pfizer’s second quarter and first six months for U.S. subsidiaries reflects the three and six months ended on June 30, 2024 and July 2, 2023, while Pfizer’s second quarter and first six months for subsidiaries operating outside the U.S. reflects the three and six months ended on May 26, 2024 and May 28, 2023.

DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this earnings release and the related attachments is as of July 30, 2024. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments.

This earnings release and the related attachments contain forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, including demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; an enterprise-wide cost realignment program, which we launched in October 2023 (including anticipated costs, savings and potential benefits); a Manufacturing Optimization Program to reduce our cost of goods sold, which we announced in May 2024 (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, including our December 2023 acquisition of Seagen, and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty (as defined in this earnings release) and our oral COVID-19 treatment (Paxlovid); our expectations regarding the impact of COVID-19 on our business, operations and financial results; and our Environmental, Social and Governance (ESG) priorities, strategies and goals. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions and we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Pfizer’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

Risks Related to Our Business, Industry and Operations, and Business Development:

• the outcome of research and development (R&D) activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from our pipeline programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations; and uncertainties regarding the future development of our product candidates, including whether or when our product candidates will advance to future studies or phases of development or whether or when regulatory applications may be filed for any of our product candidates;
• our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all;
• regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain, and the scope of, recommendations by technical or advisory committees; and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the availability or commercial potential of our products and product candidates;
• claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential;
• the success and impact of external business development activities, such as the December 2023 acquisition of Seagen, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain future financing; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired or partnered products; significant transaction costs; and unknown liabilities;
• competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;
• the ability to successfully market both new and existing products, including biosimilars;
• difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions;
• the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials;
• risks and uncertainties related to our efforts to continue to develop and commercialize Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, as well as challenges related to their manufacturing, supply and distribution, including, among others, the risk that as the market for COVID-19 products continues to become more endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, or may no longer exist, which has and may continue to lead to reduced revenues, excess inventory on-hand and/or in the channel which, for Paxlovid and Comirnaty, resulted in significant inventory write-offs in 2023 and could continue to result in inventory write-offs, or other unanticipated charges; risks related to our ability to develop and commercialize variant adapted vaccines; challenges related to the transition to the commercial market for our COVID-19 products; uncertainties related to the public’s adherence to vaccines, boosters, treatments or combinations; risks related to our ability to accurately predict or achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments; and potential third-party royalties or other claims related to Comirnaty or Paxlovid;
• trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;
• interest rate and foreign currency exchange rate fluctuations, including the impact of currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates;
• any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;
• the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain;
• any significant issues related to the outsourcing of certain operational and staff functions to third parties;
• any significant issues related to our JVs and other third-party business arrangements, including modifications or disputes related to supply agreements or other contracts with customers including governments or other payors;
• uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation or interest rate fluctuations, and recent and possible future changes in global financial markets;
• the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes;
• the impact of disruptions related to climate change and natural disasters, including uncertainties related to the impact of the tornado at our manufacturing facility in Rocky Mount, NC in 2023;
• any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences;
• the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, including our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines;
• trade buying patterns;
• the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;
• the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, including any potential future phases, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences;
• the ability to successfully achieve our climate goals and progress our environmental sustainability and other ESG priorities;

Risks Related to Government Regulation and Legal Proceedings:

• the impact of any U.S. healthcare reform or legislation or any significant spending reduction or cost control efforts affecting Medicare, Medicaid or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;
• U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive biopharmaceutical markets;
• legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;
• legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to legal proceedings and actual or alleged environmental contamination;
• the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings;
• the risk and impact of tax related litigation and investigations;
• governmental laws and regulations affecting our operations, including, without limitation, the Inflation Reduction Act of 2022, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024, and potential changes to existing tax law by the current U.S. Presidential administration and Congress, including the House-passed bill called “Tax Relief for American Families and Workers Act of 2024”;

Risks Related to Intellectual Property, Technology and Security:

• any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services);
• any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack, which may include those using adversarial artificial intelligence techniques, or other malfeasance by, but not limited to, nation states, employees, business partners or others;
• risks and challenges related to the use of software and services that include artificial intelligence-based functionality and other emerging technologies;
• the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and
• risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in patent revocation; (ii) claims of patent infringement, including asserted and/or unasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights; or (v) any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid.

Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K.

This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

The information contained on our website or any third-party website is not incorporated by reference into this earnings release. All trademarks mentioned are the property of their owners.

Certain of the products and product candidates discussed in this earnings release are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer’s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730558554/en/

Media

PfizerMediaRelations@Pfizer.com

212.733.1226

Investors

IR@Pfizer.com

212.733.4848

Source: Pfizer Inc.

FAQ

What were Pfizer's second-quarter 2024 revenues?

Pfizer's second-quarter 2024 revenues were $13.3 billion.

What is Pfizer's adjusted diluted EPS for Q2 2024?

Pfizer's adjusted diluted EPS for Q2 2024 is $0.60.

What is Pfizer's updated 2024 revenue guidance?

Pfizer's updated 2024 revenue guidance is $59.5 to $62.5 billion.

How much did Pfizer's revenues grow operationally excluding Comirnaty and Paxlovid?

Excluding Comirnaty and Paxlovid, Pfizer's revenues grew 14% operationally.

What are the expected savings from Pfizer's Manufacturing Optimization Program?

Pfizer anticipates cost savings of approximately $1.5 billion from its Manufacturing Optimization Program by the end of 2027.

How did Comirnaty revenues perform in Q2 2024?

Comirnaty revenues declined 87% operationally in Q2 2024 compared to the prior-year quarter.

What impact did the manufacturing optimization costs have on Pfizer's Q2 2024 EPS?

The $1.3 billion one-time costs for manufacturing optimization negatively impacted reported diluted EPS by $0.18.